These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27307212)

  • 1. IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection.
    O'Connor KS; Read SA; Wang M; Schibeci S; Eslam M; Ong A; Weltman MD; Douglas MW; Mazzola A; Craxì A; Petta S; Stewart GJ; Liddle C; George J; Ahlenstiel G; Booth DR
    Genes Immun; 2016 Sep; 17(6):328-34. PubMed ID: 27307212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis.
    O'Connor KS; Ahlenstiel G; Suppiah V; Schibeci S; Ong A; Leung R; van der Poorten D; Douglas MW; Weltman MD; Stewart GJ; Liddle C; George J; Booth DR
    Innate Immun; 2014 Aug; 20(6):598-605. PubMed ID: 24045339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism.
    Rogalska-Taranta M; Markova AA; Taranta A; Lunemann S; Schlaphoff V; Flisiak R; Manns MP; Cornberg M; Kraft AR; Wedemeyer H
    J Leukoc Biol; 2015 Aug; 98(2):283-94. PubMed ID: 26034208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
    Eslam M; Leung R; Romero-Gomez M; Mangia A; Irving WL; Sheridan D; Spengler U; Mollison L; Cheng W; Bugianesi E; McLeod D; Zaitoun AM; Attino V; Goeltz D; Nattermann J; Douglas M; Booth DR; George J; Ahlenstiel G
    J Hepatol; 2014 Aug; 61(2):235-41. PubMed ID: 24768758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum IFN-λ3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C.
    Imoto S; Kim SR; Amano K; Iio E; Yoon S; Hirohata S; Yano Y; Ishikawa T; Katsushima S; Komeda T; Fukunaga T; Chung H; Kokuryu H; Horie Y; Hatae T; Fujinami A; Kim SK; Kudo M; Tanaka Y
    Dig Dis; 2017; 35(6):531-540. PubMed ID: 29040985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.
    O'Connor KS; Parnell G; Patrick E; Ahlenstiel G; Suppiah V; van der Poorten D; Read SA; Leung R; Douglas MW; Yang JY; Stewart GJ; Liddle C; George J; Booth DR
    Genes Immun; 2014 Mar; 15(2):88-94. PubMed ID: 24335707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection.
    Nguyen LT; Van Nguyen D; Carr MJ; Hall WW; Nguyen LA
    Arch Virol; 2018 Jan; 163(1):115-124. PubMed ID: 29022122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood and hepatic Toll-like receptor 7 expression and interferon lambda 1 levels in chronic hepatitis C: Relation to virus replication and liver injury.
    El Aggan H; Farahat N; El Deeb N; Zeid A; El-Shendidi A
    Microb Pathog; 2019 Jun; 131():65-74. PubMed ID: 30926417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of IFNL3 and HLA-DPB1 genotype on postpartum control of hepatitis C virus replication and T-cell recovery.
    Honegger JR; Tedesco D; Kohout JA; Prasad MR; Price AA; Lindquist T; Ohmer S; Moore-Clingenpeel M; Grakoui A; Walker CM
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10684-9. PubMed ID: 27601657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
    Boglione L; Cardellino CS; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    Infect Genet Evol; 2017 Jul; 51():167-172. PubMed ID: 28315743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C.
    Asnavandi M; Zargar M; Vaziri F; Jamnani FR; Gharibzadeh S; Fateh A; Siadat SD
    Genes Immun; 2017 Sep; 18(3):144-151. PubMed ID: 28703131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C.
    Wróblewska A; Bernat A; Woziwodzka A; Markiewicz J; Romanowski T; Bielawski KP; Smiatacz T; Sikorska K
    Clin Exp Med; 2017 May; 17(2):225-232. PubMed ID: 27125837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Interferon-λ3 (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C.
    Amanzada A; Reinhardt L; Fey D; Zeisberg EM; Mihm S
    PLoS One; 2015; 10(11):e0143783. PubMed ID: 26606750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFNL3 polymorphisms and HCV infection in patients with beta thalassemia.
    Origa R; Marceddu G; Danjou F; Perseu L; Satta S; Demartis FR; Piga A; Longo F; Lai ME; Vacquer S; Galanello R
    Ann Hepatol; 2015; 14(3):389-95. PubMed ID: 25864220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
    Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
    Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients.
    Bordi L; Caglioti C; Garbuglia AR; Lapa D; Castilletti C; Taibi C; Capobianchi MR; Lalle E
    PLoS One; 2015; 10(2):e0117397. PubMed ID: 25675103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of
    Nakamoto S; Imazeki F; Kanda T; Wu S; Nakamura M; Yasui S; Tawada A; Mikata R; Chiba T; Arai M; Yokosuka O; Shirasawa H
    Int J Med Sci; 2017; 14(11):1088-1093. PubMed ID: 29104462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.